PharmiWeb.com - Global Pharma News & Resources
02-Jan-2019

Global Hepatitis B Therapeutics Market Forecast (2018-2022) with Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, GlaxoSmithKline, and Merck Sharp & Dohme Leading the Competition - ResearchAndMarkets.com

The "Global Hepatitis B Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The global hepatitis B therapeutics market is fragmented, as many pharmaceutical companies are developing drugs for the treatments of hepatitis B. Also, several companies are forming collaborations to increase their research toward the hepatitis B drug development.

These types of strategic collaboration between the pharmaceutical companies will propel the hepatitis B therapeutics development and lead to increase the growth of the market during our forecast period. This will boost the growth of the hepatitis B therapeutics market at a CAGR of over 2% during the forecast period.

Increasing prevalence of hepatitis B in infants

The increase in the prevalence of hepatitis B in infants, the companies are developing various drugs against hepatitis B virus. This leads to an increase in the global market during the forecast period.

Low accessibility due to high cost of hepatitis B treatment

One of the major problems from the treatment of hepatitis B is that not all the approved drugs are accessible to people and some are not affordable. Therefore, low accessibility due to the high cost of hepatitis B treatment is one the biggest challenges for the goal aiming to eliminate hepatitis B during our forecast period.

Key Players

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • GlaxoSmithKline
  • Merck Sharp & Dohme

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Comparison by application
  • Drugs - Market size and forecast 2017-2022
  • Vaccines - Market size and forecast 2017-2022
  • Market opportunity by application

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

  • Strategic alliances
  • Strong pipeline
  • New technological advancements

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • GlaxoSmithKline
  • Merck Sharp & Dohme

For more information about this report visit https://www.researchandmarkets.com/research/dcgndb/global_hepatitis?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005376/en/

Editor Details

Last Updated: 02-Jan-2019